A recombinant Bacillus anthracis strain producing the Clostridium perfringens Ib component induces protection against iota toxins.

Infection and Immunity
J C SirardM Mock

Abstract

The Bacillus anthracis toxinogenic Sterne strain is currently used as a live veterinary vaccine against anthrax. The capacity of a toxin-deficient derivative strain to produce a heterologous antigen by using the strong inducible promoter of the B. anthracis pag gene was investigated. The expression of the foreign gene ibp, encoding the Ib component of iota toxin from Clostridium perfringens, was analyzed. A pag-ibp fusion was introduced by allelic exchange into a toxin-deficient Sterne strain, thereby replacing the wild-type pag gene. This recombinant strain, called BAIB, was stable and secreted large quantities of Ib protein in induced culture conditions. Mice given injections of live BAIB spores developed an antibody response specific to the Ib protein. The pag-ibp fusion was therefore functional both in vitro and in vivo. Moreover, the immunized animals were protected against a challenge with C. perfringens iota toxin or with the homologous Clostridium spiroforme toxin. The protective immunity was mediated by neutralizing antibodies. In conclusion, B. anthracis is promising for the development of live veterinary vaccines.

References

Jun 6, 1991·Nature·C K StoverG F Hatfull
Aug 1, 1989·Infection and Immunity·J M Bartkus, S H Leppla
Jan 1, 1986·Toxicon : Official Journal of the International Society on Toxinology·B G Stiles, T D Wilkins
May 16, 1988·Biochemical and Biophysical Research Communications·M R Popoff, P Boquet
Mar 1, 1986·Infection and Immunity·S L WelkosP H Gibbs
May 1, 1986·Infection and Immunity·B E IvinsS H Leppla
Jan 1, 1988·Microbial Pathogenesis·S L Welkos, A M Friedlander
Jan 1, 1983·Infection and Immunity·J D Ristroph, B E Ivins
Jun 1, 1984·Vaccine·P HambletonJ Melling
Jun 1, 1995·Biologicals : Journal of the International Association of Biological Standardization·A Phalipon, P Sansonetti
Jul 1, 1995·Infection and Immunity·J R ButtertonS B Calderwood
Apr 1, 1995·Infection and Immunity·C PezardM Mock
Oct 1, 1993·Journal of General Microbiology·C PezardM Mock

❮ Previous
Next ❯

Citations

Sep 4, 1999·Journal of Applied Microbiology·F BrossierJ C Sirard
Sep 7, 2001·Annual Review of Microbiology·M Mock, A Fouet
Aug 16, 2006·Journal of Applied Microbiology·L W J Baillie
Apr 9, 2001·Infection and Immunity·D BlöckerH Barth
Feb 5, 2005·Anais Da Academia Brasileira De Ciências·Luís C S FerreiraWolfgang Schumann
Apr 14, 2006·Veterinary Research·Volker GerdtsLorne A Babiuk
Sep 9, 2004·Microbiology and Molecular Biology Reviews : MMBR·Holger BarthBradley G Stiles
Oct 12, 2001·Toxicon : Official Journal of the International Society on Toxinology·F Brossier, M Mock

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.